Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.
Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, Gobbi M, Carella AM, Gozzini A, Usala E, Cavazzini F, Danise P, Tiribelli M, Binotto G, Pregno P, Bocchia M, Gaidano G, Crugnola M, Bonifacio M, Avanzini P, Celesti F, Guella A, Martino B, Annunziata M, Luciano L, Stagno F, Vallisa D, Pungolino E, Iurlo A, Rambaldi A, Nardiello I, Orlandi E, Gambacorti-Passerini C, Alimena G. Breccia M, et al. Among authors: tiribelli m. Leuk Res. 2015 Oct;39(10):1055-9. doi: 10.1016/j.leukres.2015.07.004. Epub 2015 Jul 14. Leuk Res. 2015. PMID: 26282944 Free article.
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia. Soverini S, et al. Among authors: tiribelli m. Clin Cancer Res. 2006 Dec 15;12(24):7374-9. doi: 10.1158/1078-0432.CCR-06-1516. Clin Cancer Res. 2006. PMID: 17189410
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.
Malagola M, Damiani D, Martinelli G, Michelutti A, Cesana B, Vivo AD, Piccaluga PP, Ottaviani E, Candoni A, Geromin A, Tiribelli M, Fanin R, Testoni N, Lauria F, Bocchia M, Gobbi M, Pierri I, Zaccaria A, Zuffa E, Mazza P, Priccolo G, Gugliotta L, Bonini A, Visani G, Skert C, Bergonzi C, Roccaro AM, Filí C, Baccarani M, Russo D. Malagola M, et al. Among authors: tiribelli m. Br J Haematol. 2007 Jan;136(1):87-95. doi: 10.1111/j.1365-2141.2006.06390.x. Br J Haematol. 2007. PMID: 17222198 Free article.
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A, Martinelli G, Toffoletti E, Chiarvesio A, Tiribelli M, Malagola M, Piccaluga PP, Michelutti A, Simeone E, Damiani D, Russo D, Fanin R. Candoni A, et al. Among authors: tiribelli m. Leuk Res. 2008 Dec;32(12):1800-8. doi: 10.1016/j.leukres.2008.05.011. Epub 2008 Jul 14. Leuk Res. 2008. PMID: 18621416 Clinical Trial.
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases.
Malagola M, Peli A, Damiani D, Candoni A, Tiribelli M, Martinelli G, Piccaluga PP, Paolini S, De Rosa F, Lauria F, Bocchia M, Gobbi M, Pierri I, Zaccaria A, Zuffa E, Mazza P, Priccolo G, Gugliotta L, Bonini A, Visani G, Skert C, Bergonzi C, Roccaro AM, Filì C, Fanin R, Baccarani M, Russo D. Malagola M, et al. Among authors: tiribelli m. Eur J Haematol. 2008 Nov;81(5):354-63. doi: 10.1111/j.1600-0609.2008.01122.x. Epub 2008 Aug 19. Eur J Haematol. 2008. PMID: 18637030
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response.
Palandri F, Iacobucci I, Soverini S, Castagnetti F, Poerio A, Testoni N, Alimena G, Breccia M, Rege-Cambrin G, Tiribelli M, Varaldo R, Abruzzese E, Martino B, Luciano L, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G. Palandri F, et al. Among authors: tiribelli m. Clin Cancer Res. 2009 Feb 1;15(3):1059-63. doi: 10.1158/1078-0432.CCR-08-1195. Clin Cancer Res. 2009. PMID: 19188180 Clinical Trial.
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.
Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M; GIMEMA CML Working Party. Rosti G, et al. Among authors: tiribelli m. Blood. 2009 Dec 3;114(24):4933-8. doi: 10.1182/blood-2009-07-232595. Epub 2009 Oct 12. Blood. 2009. PMID: 19822896 Free article. Clinical Trial.
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Saglio G, et al. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525993 Free article. Clinical Trial.
185 results